mirvetuximab soravtansine-gynx (Elahere)
Jump to navigation
Jump to search
Indications
- folate receptor alpha-positive, platinum-resistant cancers
Dosage
- 6 mg/kg (based on adjusted ideal body weight) IV infusion every 3 weeks
- 5 mg/mL injection (20 mL)
Adverse effects
- common (>= 20%)
- vision impairment, keratopathy, dry eye*
- nausea, abdominal pain, diarrhea, constipation
- fatigue, peripheral neuropathy
- increased serum AST, serum ALT, & serum alkaline phosphatase
- decreased leukocyte count, neutrophil count, lymphocyte count, & blood hemoglobin
- decreased serum magnesium & serum albumin
* boxed warning of ocular toxicity
Mechanism of action
- monoclonal antibody directed against folate receptor alpha linked to a microtubule inhibitor conjugate
More general terms
References
- ↑ 1.0 1.1 FDA Drug Approvals. Nov 14, 2022 FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRa positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant
Otto MA FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Ovarian Cancer. Medscape. Nov 15, 2022 https://www.medscape.com/viewarticle/984055 - ↑ Moore KN, Oza AM, Colombo N et al Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33667670 Clinical Trial. https://www.annalsofoncology.org/article/S0923-7534(21)00157-5/fulltext